CADL - Candel Therapeutics, Inc.
IEX Last Trade
8.88
0.170 1.914%
Share volume: 41,765
Last Updated: Fri 27 Dec 2024 08:30:33 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$8.71
0.17
1.95%
Fundamental analysis
15%
Profitability
0%
Dept financing
12%
Liquidity
75%
Performance
15%
Performance
5 Days
6.26%
1 Month
85.25%
3 Months
27.18%
6 Months
55.69%
1 Year
559.71%
2 Year
519.59%
Key data
Stock price
$8.88
DAY RANGE
$8.45 - $9.73
52 WEEK RANGE
$1.25 - $14.60
52 WEEK CHANGE
$523.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Paul-Peter Tak
Region: US
Website: candeltx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: candeltx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.
Recent news